All Updates

All Updates

icon
Filter
Partnerships
Enveric Biosciences signs licensing agreement with MindBio Therapeutics to develop NPP candidate
Psychedelic Medicine
May 14, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Psychedelic Medicine

Psychedelic Medicine

May 14, 2024

Enveric Biosciences signs licensing agreement with MindBio Therapeutics to develop NPP candidate

Partnerships

  • Florida-based biotechnology company Enveric Biosciences has signed a non-binding agreement to out-license its class of novel psilocin prodrugs (NPP) to Vancouver-based biotechnology company MindBio Therapeutics.

  • Under the terms of the partnership, MindBio will leverage Enveric's NPP molecules, which are designed to release therapeutic levels of systemic psilocin, to advance the treatment of neuropsychiatric conditions like depression. Further, MindBio would undertake all future preclinical, clinical, and commercial development, paying Enveric development and sales milestones a total of USD 66.5 million upon meeting certain conditions, along with future sales royalties. Additionally, MindBio would have the right to sublicense the technology and cash buyout options as part of the agreement.

  • MindBio Therapeutics is a leading biotech company focused on developing novel treatments for mental health conditions. It specializes in microdosing psychedelic medicines and is conducting clinical trials targeting major depressive disorder and existential distress in cancer patients.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.